Literature DB >> 28653763

Pericentral hepatocytes produce insulin-like growth factor-2 to promote liver regeneration during selected injuries in mice.

Junlai Liu1,2,3, Xiao Hu2, Jie Chen4, Xinqi Li1,2,3, Lu Wang1, Binbin Wang1,2,3, Wenbo Peng1,2,3, Cuiwei Yang1,2,3, Zhijie Li1,2,3, Yan Chen5, Yue J Wang6, Chuanjiang Li5, Xiajun Li1, Fang Yan7, Yunfang Wang7, Changzhen Shang4, Xin Wang8,9,10, Tao Chen4, Pengyu Huang1.   

Abstract

Liver regeneration (LR) happens after various types of injuries. Unlike the well-studied LR caused by partial hepatectomy (PHx), there is accumulating evidence suggesting that LR during other injuries may result from unknown mechanisms. In this study, we found that insulin-like growth factor 2 (IGF-2) was drastically induced following the liver injuries caused by tyrosinemia or long-term treatments of CCl4 . However, this was not observed during the early phase of acute liver injuries after PHx or single treatment of CCl4 . Remarkably, most IGF-2-expressing hepatocytes were located at the histological area around the central vein of the liver lobule after the liver injuries caused either in fumarylacetoacetate hydrolase-deficient mice or in CCl4 chronically treated mice. Hepatocyte proliferation in vivo was significantly promoted by induced IGF-2 overexpression, which could be inhibited by adeno-associated virus-delivered IGF-2 short hairpin RNAs or linsitinib, an inhibitor of IGF-2 signaling. Proliferating hepatocytes in vivo responded to IGF-2 through both insulin receptor and IGF-1 receptor. IGF-2 also significantly promoted DNA synthesis of primary hepatocytes in vitro. More interestingly, the significantly induced IGF-2 was also found to colocalize with glutamine synthetase in the region enriched with proliferating hepatocytes for the liver samples from patients with liver fibrosis.
CONCLUSION: IGF-2 is produced by pericentral hepatocytes to promote hepatocyte proliferation and repair tissue damage in the setting of chronic liver injury, which is distinct from the signaling that occurs post-PHx. (Hepatology 2017;66:2002-2015).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28653763     DOI: 10.1002/hep.29340

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Tryptophanyl-tRNA Synthetase, a Novel Damage-Induced Cytokine, Significantly Increases the Therapeutic Effects of Endometrial Stem Cells.

Authors:  Se-Ra Park; Soo-Rim Kim; Jae-Been Im; Soyi Lim; In-Sun Hong
Journal:  Mol Ther       Date:  2020-06-19       Impact factor: 11.454

Review 2.  The many ways to mend your liver: A critical appraisal.

Authors:  Malcolm R Alison
Journal:  Int J Exp Pathol       Date:  2018-06-07       Impact factor: 1.925

3.  Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery.

Authors:  Silvia Palmisano; Natalia Rosso; Pablo J Giraudi; Michela Giuricin; Deborah Bonazza; Nicolò de Manzini; Claudio Tiribelli
Journal:  Int J Obes (Lond)       Date:  2020-09-17       Impact factor: 5.095

Review 4.  Human Amnion Epithelial Cell Therapy for Chronic Liver Disease.

Authors:  Neil Andrewartha; George Yeoh
Journal:  Stem Cells Int       Date:  2019-08-07       Impact factor: 5.443

5.  The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.

Authors:  Eleanor L Watts; Aurora Perez-Cornago; Paul N Appleby; Demetrius Albanes; Eva Ardanaz; Amanda Black; H Bas Bueno-de-Mesquita; June M Chan; Chu Chen; S A Paul Chubb; Michael B Cook; Mélanie Deschasaux; Jenny L Donovan; Dallas R English; Leon Flicker; Neal D Freedman; Pilar Galan; Graham G Giles; Edward L Giovannucci; Marc J Gunter; Laurel A Habel; Christel Häggström; Christopher Haiman; Freddie C Hamdy; Serge Hercberg; Jeff M Holly; Jiaqi Huang; Wen-Yi Huang; Mattias Johansson; Rudolf Kaaks; Tatsuhiko Kubo; J Athene Lane; Tracy M Layne; Loic Le Marchand; Richard M Martin; E Jeffrey Metter; Kazuya Mikami; Roger L Milne; Howard A Morris; Lorelei A Mucci; David E Neal; Marian L Neuhouser; Steven E Oliver; Kim Overvad; Kotaro Ozasa; Valeria Pala; Claire H Pernar; Michael Pollak; Mari-Anne Rowlands; Catherine A Schaefer; Jeannette M Schenk; Pär Stattin; Akiko Tamakoshi; Elin Thysell; Mathilde Touvier; Antonia Trichopoulou; Konstantinos K Tsilidis; Stephen K Van Den Eeden; Stephanie J Weinstein; Lynne Wilkens; Bu B Yeap; Timothy J Key; Naomi E Allen; Ruth C Travis
Journal:  Int J Cancer       Date:  2019-04-04       Impact factor: 7.396

6.  Markers of liver regeneration-the role of growth factors and cytokines: a systematic review.

Authors:  Katrin Hoffmann; Alexander Johannes Nagel; Kazukata Tanabe; Juri Fuchs; Karolin Dehlke; Omid Ghamarnejad; Anastasia Lemekhova; Arianeb Mehrabi
Journal:  BMC Surg       Date:  2020-02-12       Impact factor: 2.102

Review 7.  Hepatocyte organoids and cell transplantation: What the future holds.

Authors:  Weng Chuan Peng; Lianne J Kraaier; Thomas A Kluiver
Journal:  Exp Mol Med       Date:  2021-10-18       Impact factor: 8.718

8.  PIM1 promotes hepatic conversion by suppressing reprogramming-induced ferroptosis and cell cycle arrest.

Authors:  Yangyang Yuan; Chenwei Wang; Xuran Zhuang; Shaofeng Lin; Miaomiao Luo; Wankun Deng; Jiaqi Zhou; Lihui Liu; Lina Mao; Wenbo Peng; Jian Chen; Qiangsong Wang; Yilai Shu; Yu Xue; Pengyu Huang
Journal:  Nat Commun       Date:  2022-09-06       Impact factor: 17.694

Review 9.  The Role of Adipokines in Surgical Procedures Requiring Both Liver Regeneration and Vascular Occlusion.

Authors:  Ana Isabel Álvarez-Mercado; Esther Bujaldon; Jordi Gracia-Sancho; Carmen Peralta
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

10.  Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment.

Authors:  Xia Sun; Lizhou Jia; Tengqi Wang; Yulian Zhang; Wei Zhao; Xiangcheng Wang; Hao Chen
Journal:  J Cancer       Date:  2021-07-03       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.